In-licensing

Tiger intends to in-license a series of products (primarily medical devices) where we can add value by developing the products in China at a comparably lower cost than can be done in the West. We currently seek flexible mutually beneficial partnerships and long-term strategic collaborations to expand our product pipeline and integrate our strengths with those of others. To this end, we are looking globally for innovative product candidates.

Tiger also has a strategic partnership with Excel PharmaStudies (www.excel-china.com), the largest CRO in China, to provide development expertise at preferred pricing.

Tiger is primarily interested in in-licensing or partnering with candidates that have the following characteristics: (1) create improvements on well-established medical products or technologies; (2) $50 million-plus per annum potential; (3) have intellectual property rights;and (4) clear indication of likelihood of product success.

Out-licensing

Tiger is setting up a rich R&D pipeline for out-licensing to speed up the flow rate and maximize the value of our pipeline.

Process:

1. Contact us for non-confidential information of the project
2. Non-Disclosure Agreement execution
3. Confidential project information disclosure
4. Negotiation & agreement of key terms and the contract
5. Signing the contract
6 .Implementation

Projects:
Under Construction. Please visit us later.